Tetraphase Appoints L. Patrick Gage, Ph.D., as Chairman of the Board

Tetraphase Pharmaceuticals, Inc.

Tetraphase Appoints L. Patrick Gage, Ph.D., as Chairman of the Board

January 18, 2012

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics, today announced that L. Patrick “Pat” Gage, Ph.D., biopharmaceutical industry pioneer, has been appointed as the company’s Chairman of the Board. In this role, Dr. Gage will provide strategic leadership to the Tetraphase board of directors and work with the management team as the company advances its novel antibiotic drug candidates, which are designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens.

“I am excited to work with the Tetraphase team as its innovative chemistry platform and robust antibiotics portfolio continues to advance," said Dr. Gage. “With multiple projects in the clinic that are clearly differentiated from currently marketed antibiotics as well as from those in development by other companies, Tetraphase has the potential to help combat the worldwide health crisis driven by growing antibiotics resistance.”

“It is an honor to have Pat Gage – a senior life sciences executive with an extremely distinguished career – take on the leadership of our board of directors,” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “Pat will be an invaluable asset to Tetraphase as a professional with nearly 40 years of experience in executive, R&D, and operating leadership roles at major biotechnology and pharmaceutical companies – from Genetics Institute to Wyeth – and in serving as a board member and chairman at some of the most prestigious public and private biomedical research companies.”

Coveted by many life science organizations for his extensive experience and broad strategic insights, Dr. Gage currently serves on the boards of directors of several private and public life science companies, including serving as chairman of Cytokinetics. He also serves on the advisory board of organizations such as aTyr Pharma and Pappas Ventures.

Dr. Gage was previously employed at Hoffmann-La Roche, Inc. from 1971 and 1989, where he was Vice President of Exploratory Research from 1985 to 1989; Genetics Institute, Inc. from 1989 to 1998, where he was R&D Head and then President; and then served as President of Research at Wyeth/American Home Products Corporation (a merger of Genetics Institute and Wyeth Pharmaceuticals) until 2002.

Dr. Gage received his S.B. in physics from Massachusetts Institute of Technology and his Ph.D. in biophysics from the University of Chicago. He completed his postdoctoral research at the Carnegie Institution of Washington, Baltimore, in 1971.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug resistant and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit www.tphase.com.